Cargando…
Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium‐glucose co‐transporter‐2 inhibitors in the USA: A retrospective cohort study
AIMS: To examine the incidence of amputation in patients with type 2 diabetes mellitus (T2DM) treated with sodium glucose co‐transporter 2 (SGLT2) inhibitors overall, and canagliflozin specifically, compared with non‐SGLT2 inhibitor antihyperglycaemic agents (AHAs). MATERIALS AND METHODS: Patients w...
Autores principales: | Yuan, Zhong, DeFalco, Frank J., Ryan, Patrick B., Schuemie, Martijn J., Stang, Paul E., Berlin, Jesse A., Desai, Mehul, Rosenthal, Norm |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836890/ https://www.ncbi.nlm.nih.gov/pubmed/28898514 http://dx.doi.org/10.1111/dom.13115 |
Ejemplares similares
-
Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real‐world meta‐analysis of 4 observational databases (OBSERVE‐4D)
por: Ryan, Patrick B., et al.
Publicado: (2018) -
Renal safety of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus
por: Desai, Mehul, et al.
Publicado: (2017) -
Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co‐transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases
por: Wang, Lu, et al.
Publicado: (2019) -
Risk of lower extremity amputations in patients with type 2 diabetes using sodium-glucose co-transporter 2 inhibitors
por: Zerovnik, Spela, et al.
Publicado: (2021) -
On Amputation in Cases of Gangrene of the Lower Extremity
por: Caird, Francis M.
Publicado: (1893)